FN2 Earnings Intelligence

BridgeBio Pharma, Inc. earnings overview

Latest BridgeBio Pharma, Inc. (BBIO) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.

Next reportBridgeBio Pharma, Inc. reports Wednesday, Oct 28, 2026 · After market closeConsensus EPS $-0.67 · consensus revenue $269.0M
BBIO FY2026 Q2 · Calendar Q3 2026

BridgeBio Pharma, Inc.

BridgeBio's Q2 supports a constructive operating trajectory: Attruby growth, kidney-protection evidence, a strong financing, and three programs in FDA review provide multiple potential growth drivers. The thesis remains dependent on launch execution, patient identification, regulatory progress, and the company's ability to defend ATTR positioning amid competition.

EPS surprise-35.5%
Market move-1.1%

Get the BBIO recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.